Join date: May 18, 2022


Soe Hok Gie Sekali Lagi.pdf ===> DOWNLOAD

Soe Hok Gie Sekali Lagi.pdf ===> DOWNLOAD

by A Azis 04-Oct-2019 5kghs9qghljn. . 5kghs9qghljn. Soe Hok Gie Sekali Lagi.pdf by A Azis 02-Jan-2016 fkqrsq5hpsr.Beneficial effect of subconjunctival bevacizumab administration on corneal inflammation in a murine model of Sjögren's syndrome. To assess the potential beneficial effect of anti-vascular endothelial growth factor (VEGF) therapy on corneal inflammation in a mouse model of Sjögren's syndrome (SS). SS was induced in BALB/c mice by injection of interleukin 2 receptor alpha-chain (IL-2Rα) transgenic T cells. After 5 weeks of IL-2Rα-cell transfer, mice were divided into two groups: one group received bevacizumab (anti-VEGF; 2.5 mg/mice/injection) twice a week for 4 weeks; and the other group received phosphate-buffered saline. Corneal epithelium damage and lymphocytic infiltration were assessed by fluorescein and immunohistochemistry. Endothelial cell density and pericyte coverage were evaluated by histomorphometry. Corneal thickness was measured using an ultrasonic pachymeter. Vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF)-1α were assessed by immunostaining. Bevacizumab treatment reduced the occurrence of intercellular adhesion molecule 1 (ICAM-1)-positive corneal epithelium damage and lymphocyte infiltration in SS mice. Moreover, in vivo bevacizumab treatment significantly decreased VEGF and HIF-1α expression. Corneal epithelial cell loss and endothelial cell loss were significantly reduced by bevacizumab treatment in SS mice. Moreover, subconjunctival bevacizumab administration significantly reduced corneal thickness in SS mice. The present results suggest that subconjunctival bevacizumab administration exerts a beneficial effect on corneal inflammation



Soe Hok Gie Sekali Lagi.pdf ((LINK))

More actions